Return to Directory

Christopher Kepley

Chris Kepley

Christopher Kepley, Ph.D.

About Professor Kepley


Chris Kepley is an Associate Professor the University of North Carolina at Greensboro (UNCG), Joint School of Nanoscience and Nanoengineering. He is also the Co-Founder of Kepley BioSystems Incorporated which was formed 2013. He was previously Group Leader of NanoImmunology at Luna Innovations Incorporated. Dr. Kepley is a leading expert in inflammatory mechanisms and using nanomaterials for diagnostic, therapeutic, and theranostic applications. Based on a recent discovery in his lab he is investigating a new patent-pending cancer immunotherapy strategy for breast cancer. He has over 80 peer-reviewed publications, several issued and pending patents, and serves on the editorial board for several journals. His research was recognized internationally as the recipient of the 2010 Phadia Allergy Research Forum Award, the most prestigious international award in allergy research; and the 2004 Henning Løwenstein International Research Award for excellence in allergy research. More recently he was asked to present his research alongside two Nobel Laureates at the 2015 World Fullerene Conference in Hohhot China. He is a Fellow of the American Academy of Allergy, Asthma and Immunology, serves on the Research Advisory Board for the Food Allergy and Anaphylaxis Network, and is a former Parker B. Francis Fellow in Respiratory Research. Dr. Kepley received his PhD in Microbiology and Immunology from Virginia Commonwealth University, an MBA from the College of William and Mary, and a BS in Biology from James Madison University.


Dr. Kepley’s current research interests

  1. A new cell-based breast cancer immunotherapy
  2. Mechanism of action of a novel gold-based nanomedicine with re-myelinating properties
  3. The effects of nanomaterials on the immune system
  4. Mechanisms of allergy, mast cells, and Fc receptors
  5. Sustainable environmental solution

Dr. Kepley’s Research Team

Jesse Plotkin
A new autologous cancer immunotherapy

Meenakshi Agarwal
A new autologous cancer immunotherapy

Michael Elias
A new autologous cancer immunotherapy

Vandana Garikipati
Mechanism of action of the re-myelinating gold-based nanomedicine

Getachew Tedla
A new nanotheranostic for glioblastoma


NF-κB inhibitors that prevent foam cell formation and atherosclerotic plaque accumulation.
Plotkin JD, Elias MG, Dellinger AL, Kepley CL.
Nanomedicine : nanotechnology, biology, and medicine. 2017; 13(6):2037-2048.
PubMed [journal] PMID: 28457935

Antigenic Determinants of the Bilobal Cockroach Allergen Bla g 2.
Woodfolk JA, Glesner J, Wright PW, Kepley CL, Li M, Himly M, Muehling LM, Gustchina A, Wlodawer A, Chapman MD, Pomés A.
The Journal of biological chemistry. 2016; 291(5):2288-301.
PubMed [journal] PMID: 26644466 PMCID: PMC4732212

Surface plasmon resonance: a label-free tool for cellular analysis.
Zeidan E, Kepley CL, Sayes C, Sandros MG.
Nanomedicine (London, England). 2015; 10(11):1833-46.
PubMed [journal ]PMID: 26080702

Inhibition of inflammatory arthritis using fullerene nanomaterials.
Dellinger AL, Cunin P, Lee D, Kung AL, Brooks DB, Zhou Z, Nigrovic PA, Kepley CL.
PloS one. 2015; 10(4):e0126290.
PubMed [journal]PMID: 25879437 PMCID: PMC4400016

Study examining fullerene toxicity raises questions as to the purity of the nanomaterials and erroneous experimental conclusions.
Kepley C, Dellinger A.
Toxicological sciences : an official journal of the Society of Toxicology. 2014; 141(2):326-7.
PubMed [journal] PMID: 25288704  PMCID: PMC4830230

A steroid-mimicking nanomaterial that mediates inhibition of human lung mast cell responses.
Dellinger AL, Zhou Z, Kepley CL.
Nanomedicine : nanotechnology, biology, and medicine. 2014; 10(6):1185-93. NIHMSID: NIHMS570031
PubMed [journal] PMID: 24566277  PMCID: PMC4119857

IL-33/ST2 axis promotes mast cell survival via BCLXL.
Wang JX, Kaieda S, Ameri S, Fishgal N, Dwyer D, Dellinger A, Kepley CL, Gurish MF, Nigrovic PA.
Proceedings of the National Academy of Sciences of the United States of America. 2014; 111(28):10281-6.

A novel gadolinium-based trimetasphere metallofullerene for application as a magnetic resonance imaging contrast agent.
Adiseshaiah P, Dellinger A, MacFarland D, Stern S, Dobrovolskaia M, Ileva L, Patri AK, Bernardo M, Brooks DB, Zhou Z, McNeil S, Kepley C.
Investigative radiology. 2013; 48(11):745-54. PubMed [journal]PMID: 23748228

Application of fullerenes in nanomedicine: an update.
Dellinger A, Zhou Z, Connor J, Madhankumar AB, Pamujula S, Sayes CM, Kepley CL.
Nanomedicine (London, England). 2013; 8(7):1191-208. PubMed [journal]PMID: 23837857

Functionalization of gadolinium metallofullerenes for detecting atherosclerotic plaque lesions by cardiovascular magnetic resonance.
Dellinger A, Olson J, Link K, Vance S, Sandros MG, Yang J, Zhou Z, Kepley CL.
Journal of cardiovascular magnetic resonance : official journal of the Society for Cardiovascular Magnetic Resonance. 2013; 15:7.
PubMed [journal]PMID: 23324435 PMCID: PMC3562260

Complete list of Dr. Kepley’s publications can be found here.

Funding Sources

  • National Science Foundation (NSF)
  • National Institute of Health (NIH)
  • North Carolina Biotechnology Center (NCBC)
  • University of North Carolina GREENSBORO, GIANT STEPS INITIATIVE
  • American Lung Association
  • Francis Family Foundations
  • Food Allergy and Anaphylaxis Network Research

Press Releases

Article in Natural Triad Magazine on “Meat allergy”

“Goodbye, herring? Biotech bait gives lobstermen alternative”, Associated Press, Aug. 26, 2016,

“A Stinky Artificial Bait Could Protect Millions of Tiny Fish”, Scientific America, 2016,


“Synthetic Bait Could be Future Fishing for Anglers”, 2016, Spectrum News,

“NC IDEA Foundation Selects Eleven Finalists from Across the State in Fall 2016 Seed Grant Cycle”, NC Idea Press release,

“Consider the lobsters supper”, New Food Economy, 2016,

“Company Profile: Greensboro Firm Develops Synthetic Bait for Lobster, Crab Fisheries”, 2016, North Carolina Biotech,

“Look out lobsters — science is coming to get ya”, Local Express, 2016

“Artificial lobster bait to be tested in Nova Scotia waters”, CBC News, 2016,

“Startup’s synthetic lobster, crab bait could boost supplies of forage fish”, Undercurrent News, 2016,


“Building better bait: Greensboro start-up invents new lure for crabs and lobsters”, 2017, Greensboro News and Record,

“DCC Nanotechnology Student Helps Formulate Patent For Synthetic Crab Bait”, 2014

“Allergy Nanomedicine: Buckyballs dampen response of cells that trigger allergic reactions” Science News, 2007.

“Can Buckyballs Improve Your Health?”, Health News Digest, 2007,

“Buckyball therapy”, Roanoke Times, 2007,

“A Therapy for Cat Allergies, Thanks to Mice”, New York Times, 2005,

“Former Roanoker wins prestigious international allergy award” Roanoke Times, 2004,

“Allergy-fighting buckyballs created”, 2007, UPI.

“Buckyballs could help fight allergies”, 2007, Nature News,           

“Researchers Develop Buckyballs to Fight Allergy”, 2007, VCU News,

“PHARF 2010 International Allergy Research Award”, EAACI, 2010,

“The First AAAAI Award for Outstanding Research Published in the JACI by a Developing Researcher”, JACI press release, 2001,